AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15825788 — intervention group
Group type: COMPARATOR
Intervention: Ligature wires
Number of subjects: 21
Study 15825788 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 21
Study 12187499 — intervention group
Group type: COMPARATOR
Intervention: Antiretrovirals (d4T, ddI, EFV, ABC)
Number of subjects: 69
Study 12187499 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretrovirals + Hydroxyurea (HU)
Number of subjects: 69
Study 12187499 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretrovirals + Hydroxyurea (HU) + Interleukin-2 (IL-2)
Number of subjects: 69
Study 12187499 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretrovirals alone or in combination with HU and IL-2
Number of subjects: 69
Study 10609719 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal sonography, Pipelle endometrial biopsy, outpatient hysteroscopy
Number of subjects: 400
Study 10609719 — intervention group
Group type: COMPARATOR
Intervention: Hysteroscopy
Number of subjects: 400
Study 10609719 — intervention group
Group type: COMPARATOR
Intervention: Outpatient Pipelle
Number of subjects: 400
Study 10609719 — intervention group
Group type: COMPARATOR
Intervention: Outpatient procedures
Number of subjects: 400
Study 8695837 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine (30 mg/kg/d, days 1 to 5; continuous intravenous infusion beginning 24 hours before mitoxantrone infusion)
Number of subjects: 315
Study 8695837 — intervention group
Group type: COMPARATOR
Intervention: Control group (mitoxantrone 12 mg/m2/d, days 2 to 5 and cytarabine 1 g/m2/12 h, days 1 to 5)
Number of subjects: 315
Study 8695837 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 315
Study 8695837 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine group
Number of subjects: 315
Study 1752115 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta (intravenous)
Number of subjects: 18
Study 1752115 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta (subcutaneous)
Number of subjects: 18
Study 6122483 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 53
Study 6122483 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol
Number of subjects: 53
Study 6122483 — intervention group
Group type: EXPERIMENTAL
Intervention: propranolol
Number of subjects: 53
Study 6122483 — intervention group
Group type: EXPERIMENTAL
Intervention: oxprenolol
Number of subjects: 53
Study 6122483 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid (soya oil) clearance
Number of subjects: 53
Study 6122483 — intervention group
Group type: EXPERIMENTAL
Intervention: initially reduced HDL cholesterol
Number of subjects: 53
Study 6122483 — intervention group
Group type: EXPERIMENTAL
Intervention: initially raised free fatty acid concentrations
Number of subjects: 53
Study 30679284 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to mobile phone
Number of subjects: 423
Study 30679284 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to receive mobile phone-based health services
Number of subjects: 423
Study 30679284 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational status
Number of subjects: 423
Study 30679284 — intervention group
Group type: EXPERIMENTAL
Intervention: Route of medication
Number of subjects: 423
Study 30679284 — intervention group
Group type: EXPERIMENTAL
Intervention: Transportation mechanism
Number of subjects: 423
Study 30679284 — intervention group
Group type: EXPERIMENTAL
Intervention: Travel time to health facility
Number of subjects: 423
Study 30679284 — intervention group
Group type: EXPERIMENTAL
Intervention: Current use of mobile phone as appointment reminder
Number of subjects: 423
Study 30679284 — intervention group
Group type: EXPERIMENTAL
Intervention: Locking mobile phone with passwords
Number of subjects: 423
Study 28596043 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 200 mg
Number of subjects: 1862
Study 28596043 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg
Number of subjects: 1862
Study 28596043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1862
Study 28596043 — intervention group
Group type: COMPARATOR
Intervention: Etanercept 50 mg
Number of subjects: 1862
Study 25601538 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecallantide
Number of subjects: 50
Study 25601538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 23900311 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR C677T T-allele carriers with traumatic childhood events (T+ and TCE+)
Number of subjects: 789
Study 23900311 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR C677T non-carriers with traumatic childhood events (T- and TCE+)
Number of subjects: 789
Study 23900311 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR C677T T-allele carriers without traumatic childhood events (T+ and TCE-)
Number of subjects: 789
Study 23900311 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR C677T non-carriers without traumatic childhood events (T- and TCE-)
Number of subjects: 789
Study 23900311 — intervention group
Group type: COMPARATOR
Intervention: MTHFR genotype and TCEs interaction on depressive symptomatology in healthy individuals
Number of subjects: 789
Study 21107436 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic heart disease (IHD)
Number of subjects: 24379
Study 21107436 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic stroke
Number of subjects: 24379
Study 21107436 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of hypertension
Number of subjects: 24379
Study 21107436 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of diabetes mellitus
Number of subjects: 24379
Study 21107436 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of hypercholesterolemia
Number of subjects: 24379
Study 19501900 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (n=2220)
Number of subjects: 4447
Study 19501900 — intervention group
Group type: COMPARATOR
Intervention: Active control (combination of metformin and sulfonylurea, n=2227)
Number of subjects: 4447
Study 19501900 — intervention group
Group type: COMPARATOR
Intervention: Active control (n=2227)
Number of subjects: 4447
Study 18219833 — intervention group
Group type: EXPERIMENTAL
Intervention: Santana apple
Number of subjects: 15
Study 18219833 — intervention group
Group type: COMPARATOR
Intervention: Golden Delicious apple
Number of subjects: 15
Study 18219833 — intervention group
Group type: COMPARATOR
Intervention: Topaz apple
Number of subjects: 15
Study 12579025 — intervention group
Group type: EXPERIMENTAL
Intervention: One-step povidone-iodine topical gel
Number of subjects: 50
Study 12579025 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step iodophor scrub followed by povidone-iodine paint
Number of subjects: 50
Study 10594395 — intervention group
Group type: EXPERIMENTAL
Intervention: Maalox
Number of subjects: 94
Study 10594395 — intervention group
Group type: COMPARATOR
Intervention: ranitidine
Number of subjects: 94
Study 8694726 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost once daily
Number of subjects: 184
Study 8694726 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol maleate twice daily
Number of subjects: 184
Study 1874212 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 0.25 microgram kg‐1 min‐1
Number of subjects: 44
Study 1874212 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 0.50 microgram kg‐1 min‐1
Number of subjects: 44
Study 1874212 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 0.75 microgram kg‐1 min‐1
Number of subjects: 44
Study 1874212 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 20‐200 mg h‐1
Number of subjects: 44
Study 1874212 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of propofol and alfentanil
Number of subjects: 44
Study 6128776 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg propranolol
Number of subjects: 10
Study 6128776 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg pindolol
Number of subjects: 10
Study 6128776 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg metoprolol
Number of subjects: 10
Study 6128776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6128776 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha blockade (preceding all interventions)
Number of subjects: 10
Study 31677181 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) plus metformin
Number of subjects: 10
Study 31677181 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus metformin (Plac/Met)
Number of subjects: 10
Study 31358588 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin-based combination therapy (ACT); specific details on dosage and duration not provided.
Number of subjects: 1399
Study 28648417 — intervention group
Group type: EXPERIMENTAL
Intervention: HFRT + SCT
Number of subjects: 70
Study 28648417 — intervention group
Group type: COMPARATOR
Intervention: SCT-alone
Number of subjects: 70
Study 26209863 — intervention group
Group type: EXPERIMENTAL
Intervention: ENG implant inserted within 48 h after delivery
Number of subjects: 24
Study 26209863 — intervention group
Group type: COMPARATOR
Intervention: Control group (absence of contraceptive method)
Number of subjects: 24
Study 23819701 — intervention group
Group type: EXPERIMENTAL
Intervention: CHANGE! intervention
Number of subjects: 318
Study 22168507 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised cognitive behavioural therapy (CCBT)
Number of subjects: 24
Study 22168507 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 24
Study 19448579 — intervention group
Group type: EXPERIMENTAL
Intervention: SenSura appliances
Number of subjects: 148
Study 19448579 — intervention group
Group type: COMPARATOR
Intervention: Reference appliances
Number of subjects: 148
Study 17135811 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life‐AD
Number of subjects: 644
Study 17135811 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life Activity Inventory
Number of subjects: 644
Study 17135811 — intervention group
Group type: EXPERIMENTAL
Intervention: SF‐36
Number of subjects: 644
Study 17135811 — intervention group
Group type: EXPERIMENTAL
Intervention: SF‐12
Number of subjects: 644
Study 17135811 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with Life Scale
Number of subjects: 644
Study 15123224 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 15
Study 10510951 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 19
Study 10510951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 8541472 — intervention group
Group type: EXPERIMENTAL
Intervention: 'Theory of mind' condition
Number of subjects: 9
Study 8541472 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (visual and semantic attributes of known objects)
Number of subjects: 9
Study 8541472 — intervention group
Group type: COMPARATOR
Intervention: Condition inferring function of an unfamiliar object from its form
Number of subjects: 9
Study 1945579 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-T mixed with DTP vaccine in a single syringe (Group A)
Number of subjects: 278
Study 1945579 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-T given in one arm and DTP in the other arm (Group B)
Number of subjects: 278
Study 1945579 — intervention group
Group type: COMPARATOR
Intervention: DTP given in one arm and placebo in the other (Group C)
Number of subjects: 278
Study 7021072 — intervention group
Group type: EXPERIMENTAL
Intervention: 550 mg naproxen sodium
Number of subjects: 19
Study 7021072 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg soluble aspirin
Number of subjects: 19
Study 7021072 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 19
Study 31449168 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (36-144 μg/dl forearm volume per minute) for 15-60 minutes
Number of subjects: 10
Study 31449168 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin (100 and 1000 pmol/min) with and without bevacizumab (144 μg/dl forearm volume per minute)
Number of subjects: 10
Study 31449168 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ-123 (10 nmol/min) with bradykinin
Number of subjects: 10
Study 30590565 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-expandable valves (BE)
Number of subjects: 12381
Study 30590565 — intervention group
Group type: COMPARATOR
Intervention: Self-expandable valves (SE)
Number of subjects: 12381
Study 30590565 — intervention group
Group type: EXPERIMENTAL
Intervention: New-generation balloon-expandable valves (BE)
Number of subjects: 12381
Study 30590565 — intervention group
Group type: COMPARATOR
Intervention: New-generation self-expandable valves (SE)
Number of subjects: 12381
Study 30062716 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol (2 μg/day for 24 weeks)
Number of subjects: 168
Study 30062716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 26634323 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First (HF) intervention
Number of subjects: 1162
Study 25121719 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 17
Study 25121719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 22978098 — intervention group
Group type: EXPERIMENTAL
Intervention: Yupei Qisun Sequential Method (YQSM) combined with IVF/ICSI
Number of subjects: 60
Study 22978098 — intervention group
Group type: COMPARATOR
Intervention: IVF/ICSI alone (Control)
Number of subjects: 60
Study 20139233 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (75 mg/d) in elderly men
Number of subjects: 144
Study 20139233 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (5 mg/d) in elderly men
Number of subjects: 144
Study 20139233 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (50 mg/d) in elderly women
Number of subjects: 144
Study 20139233 — intervention group
Group type: COMPARATOR
Intervention: Placebo in elderly men
Number of subjects: 144
Study 20139233 — intervention group
Group type: COMPARATOR
Intervention: Placebo in elderly women
Number of subjects: 144
Study 17438317 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin
Number of subjects: 3846
Study 15625147 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 50 microg every 6 hours x 2 doses
Number of subjects: 111
Study 15625147 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinoprostone gel 0.5 mg every 6 hours x 2 doses
Number of subjects: 111
Study 15625147 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinoprostone pessary 10 mg x 1 dose for 12 hours
Number of subjects: 111
Study 12383570 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg)
Number of subjects: 36
Study 12383570 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) (10 mg)
Number of subjects: 36
Study 12383570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 10432918 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.22-micron filter
Number of subjects: 0
Study 10432918 — intervention group
Group type: COMPARATOR
Intervention: Cigarette filter
Number of subjects: 0
Study 10432918 — intervention group
Group type: COMPARATOR
Intervention: 20-micron filter
Number of subjects: 0
Study 7587005 — intervention group
Group type: EXPERIMENTAL
Intervention: Pears
Number of subjects: 61
Study 7587005 — intervention group
Group type: EXPERIMENTAL
Intervention: Apples
Number of subjects: 61
Study 7587005 — intervention group
Group type: EXPERIMENTAL
Intervention: Oranges
Number of subjects: 61
Study 7587005 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapes
Number of subjects: 61
Study 7587005 — intervention group
Group type: EXPERIMENTAL
Intervention: Plums
Number of subjects: 61
Study 7587005 — intervention group
Group type: EXPERIMENTAL
Intervention: Peaches
Number of subjects: 61
Study 7587005 — intervention group
Group type: EXPERIMENTAL
Intervention: Apricots
Number of subjects: 61
Study 7587005 — intervention group
Group type: EXPERIMENTAL
Intervention: Bananas
Number of subjects: 61
Study 31243258 — intervention group
Group type: COMPARATOR
Intervention: Single application of platelet-rich plasma (PRP)
Number of subjects: 35
Study 31243258 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple application of platelet-rich plasma (PRP)
Number of subjects: 35
Study 26677237 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 108
Study 26677237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 24021691 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 463
Study 21278555 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (CFNB)
Number of subjects: 0
Study 21278555 — intervention group
Group type: COMPARATOR
Intervention: Extended release epidural morphine (DepoDur)
Number of subjects: 0
Study 21278555 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CFNB and DepoDur
Number of subjects: 0
Study 19038468 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant and adjuvant short-term hormonal treatments with curative radiotherapy
Number of subjects: 0
Study 19038468 — intervention group
Group type: EXPERIMENTAL
Intervention: Dummy run procedure combined with individual case review
Number of subjects: 0
Study 17939933 — intervention group
Group type: EXPERIMENTAL
Intervention: Management strategies for mucocutaneous HSV-induced disease
Number of subjects: 0
Study 15491386 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 13
Study 11557912 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus as part of a cyclosporine-prednisone immunosuppressive regimen
Number of subjects: 673
Study 11557912 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus with concomitant erythromycin or azithromycin
Number of subjects: 673
Study 11557912 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus with concomitant itraconazole
Number of subjects: 673
Study 11557912 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus in black patients
Number of subjects: 673
Study 11557912 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus adjusted for covariates
Number of subjects: 673
Study 9632444 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive management (routine coronary angiography followed by myocardial revascularization)
Number of subjects: 920
Study 9632444 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (medical therapy and noninvasive testing, with subsequent invasive management if indicated)
Number of subjects: 920
Study 9632444 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive management
Number of subjects: 920
Study 9632444 — intervention group
Group type: COMPARATOR
Intervention: Overall mortality during follow-up
Number of subjects: 920
Study 8152446 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodiol (13 to 15 mg per kilogram of body weight per day)
Number of subjects: 145
Study 8152446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 3349297 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior lesser curve seromyotomy with posterior truncal vagotomy (ASPTV)
Number of subjects: 91
Study 3349297 — intervention group
Group type: COMPARATOR
Intervention: Proximal gastric vagotomy (PGV)
Number of subjects: 91
Study 30452732 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Mouth Spray (NMS)
Number of subjects: 1198
Study 30452732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1198
Study 29072086 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT)
Number of subjects: 24
Study 29072086 — intervention group
Group type: COMPARATOR
Intervention: Education intervention (Control)
Number of subjects: 24
Study 28406746 — intervention group
Group type: EXPERIMENTAL
Intervention: NBP607-QIV
Number of subjects: 1503
Study 28406746 — intervention group
Group type: COMPARATOR
Intervention: NBP607-Y
Number of subjects: 1503
Study 28406746 — intervention group
Group type: COMPARATOR
Intervention: NBP607-V
Number of subjects: 1503
Study 26242122 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative medicine treatment group (anti‐virus Western medicine plus CQG)
Number of subjects: 30
Study 26242122 — intervention group
Group type: COMPARATOR
Intervention: Western medicine treatment group (treated with anti‐virus Western medicine)
Number of subjects: 30
Study 22966096 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional recombinant human epidermal growth factor (rhEGF)
Number of subjects: 0
Study 22966096 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 20935586 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive addition lenses (PALs)
Number of subjects: 85
Study 20935586 — intervention group
Group type: COMPARATOR
Intervention: Single vision lenses (SVLs)
Number of subjects: 85
Study 18394900 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Renal Replacement Therapy (CRRT)
Number of subjects: 0
Study 18394900 — intervention group
Group type: COMPARATOR
Intervention: Intermittent Haemodialysis (IHD)
Number of subjects: 0
Study 18394900 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid therapies
Number of subjects: 0
Study 16878257 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotyping-based treatment switch (group 1)
Number of subjects: 74
Study 16878257 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (group 2)
Number of subjects: 74
Study 12804345 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercises (walking or stationary cycling) or a combination of aerobic plus spinal flexibility exercises for 1 hour 3 days a week for 3 months
Number of subjects: 114
Study 10678643 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal breathing method (PC20 value of <=8.0 mg x mL(‐1))
Number of subjects: 47
Study 10678643 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefar dosimeter protocol (PD20 value of <=0.5 mg)
Number of subjects: 47
Study 8888830 — intervention group
Group type: EXPERIMENTAL
Intervention: yoked base-up and base-in prism combined with plus power lenses
Number of subjects: 30
Study 1324645 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg once daily for 3 days)
Number of subjects: 50
Study 1324645 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (500 mg three times daily for 5 days)
Number of subjects: 50